Association Between Perioperative Platelet Function and Major Adverse Perioperative Events

The Association Between Perioperative Platelet Inhibition (Function) and Major Adverse Perioperative Cardiac Events in Post Percutaneous Coronary Intervention Patients Undergoing Non-cardiac Surgery

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00901030

Enrollment

250

Registered

2009-05-13

Start date

2009-03-01

Completion date

2015-09-01

Last updated

2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Keywords

platelet function, perioperative complications, thromboelastography, coronary stents, non-cardiac surgery

Brief summary

This study will examine the degree of blood thinning (platelet function) in patients coming for non-cardiac surgery on antiplatelet agents using platelet function tests called thromboelastography (TEG) and platelet mapping assay (PMA) and major cardiac complications that occur any time after surgery (perioperative).

Detailed description

Patients who have had stents in their coronary arteries (PCI) have to stay on antiplatelet agents to prevent clotting of their stents. These patients often require non-cardiac surgery (NCS) at some stage after their PCI. The rate of major cardiac complications (MACE)in this population is very high and it is unclear why they are at higher risk than the general population. It is possible their antiplatelet is not adequate, or that surgery causes them to be more clot prone. This is a prospective, multicentre observational study.

Interventions

PROCEDUREBlood drawn

Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

* patients between ages 30-85 years old, receiving post-PCI aspirin and/or clopidogrel therapy * patients undergoing non-ambulatory, NCS * patients will have received a bare metal coronary stent within the last 12 months or a drug eluting stent at any time prior to their NCS * the type of surgery has to be such that there are no contra-indictions to remain on an anti-platelet agent * surgeon must agree to keep the patient on at least one anti-platelet agent during the perioperative period

Exclusion criteria

* clotting abnormalities * drugs affecting platelet function other than aspirin or clopidogrel * moderate renal impairment * liver dysfunction with co-existing thrombocytopenia

Design outcomes

Primary

Measure	Time frame
Relationship between platelet function and MACE during the perioperative period	1 month

Secondary

Measure	Time frame
Association of MACE with perioperative platelet function as measured by TEG and PMA	1 month

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORSummer Syed, M.D.

Hamilton Health Sciences Corporation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026